Biotech Startups

Reunion Neuroscience is a clinical-stage biopharmaceutical company developing serotonergic psychedelic therapies for mental health conditions such as postpartum depression, adjustment disorder, and generalized anxiety disorder. Its lead candidate, luvesilocin (RE104), is a short-duration prodrug of 4-OH-DiPT that targets the serotonin 2A receptor.

4 investors

RhyGaze develops gene therapies using optogenetic proteins to restore sight in patients with vision loss caused by retinal photoreceptor dysfunction. The company combines optogenetic technology with gene therapy delivery methods to enable light detection in degenerative eye conditions.

4 investors

Riskgaming creates immersive strategy simulation games where high-level decision-makers assume roles and navigate complex scenarios involving technology, business, and geopolitical challenges to explore alternative outcomes and inform real-world decisions.

4 investors

Roivant develops pharmaceutical medicines and medical technologies through a subsidiary model called "Vants," focused on accelerating the development and commercialization of treatments for dermatology and other therapeutic areas. The company operates as a biopharmaceutical holding with multiple focused companies advancing drug candidates through clinical trials and commercial launch.

4 investors

Rondo Therapeutics is an immuno-oncology biopharmaceutical company developing bispecific/multispecific antibody therapeutics designed for tumor-selective targeting to treat solid tumors while sparing healthy tissue. Its therapies aim to expand the therapeutic window for eradicating tumors.

4 investors

Route 92 Medical develops neurointervention catheter systems and devices aimed at improving outcomes for neurovascular patients, including stroke treatment. Its products are designed to navigate tortuous vascular anatomy and reach target locations for procedures such as aspiration.

4 investors

Royalty Pharma acquires and manages pharmaceutical royalties from approved drugs and therapies, providing investors exposure to the biopharma sector without early-stage development risk. The company operates as a market leader in the pharmaceutical royalty market with a diversified portfolio of long-duration revenue streams.

4 investors

RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease. It focuses on immunocompromised populations such as newborns, the elderly, and patients with weakened immunity who may not respond well to seasonal vaccines.

4 investors

SAGA Diagnostics develops molecular residual disease testing for cancer detection, combining genomic expertise to identify cancer at early treatable stages. The company serves oncology and treatment decision-making in the healthcare sector.

4 investors

Sagimet is a clinical-stage biopharmaceutical company developing therapies targeting fatty acid synthase (FASN) for metabolic diseases and oncology. The company advances drug candidates through clinical trials in areas such as metabolic disease.

4 investors

SanaHeal develops soft-material and bioadhesive technologies, such as hemostatic and tissue-regeneration solutions, for medical device applications. The company focuses on translating biomaterials research into commercial products to address challenges in human health.

4 investors

Sangamo Therapeutics develops gene-editing therapeutics using zinc finger and modular integrase platforms to treat genetic diseases including hemophilia, Fabry disease, and neuropathy. The company is currently undergoing Chapter 11 reorganization and conducting clinical trials for various therapeutic applications.

4 investors

Santa Ana Bio is a biotech company developing engineered antibody therapeutics that target the immune pathways and cells driving autoimmune and inflammatory diseases. It is building a pipeline of first-in-class and best-in-class biologics for conditions such as inflammatory bowel disease and scleroderma-associated interstitial lung disease.

4 investors

Satellite Bio develops an off-the-shelf cell therapy that delivers functional liver cells (hepatocytes) into the body, where they engraft to restore liver function. The therapy targets patients with severe liver diseases and hepatic insufficiency who lack effective treatment options.

4 investors

Scioto Biosciences is a life sciences company with corporate offices and research facilities in Fishers, Indiana. This page describes its office locations and employee benefits rather than detailing its products.

4 investors

SeaStar Medical develops the Selective Cytopheretic Device (SCD), a therapy that targets highly activated neutrophils and monocytes to neutralize the hyperinflammatory immune response in critically ill ICU patients facing conditions such as infection, trauma, or surgery. The device integrates with existing hemodialysis delivery systems and is aimed at reducing dependency on dialysis and time in the ICU.

4 investors

Semarion is a University of Cambridge spin-out developing the SemaCyte platform, which converts adherent cells into barcoded, ready-to-use reagents for accelerated drug discovery and cell-based research. The platform combines materials engineering and cell biology to enable researchers to multiplex cell models and increase throughput in pharmaceutical assays.

4 investors

Septerna is a biotechnology company that uses its proprietary Native Complex Platform to discover and develop oral small molecule therapies targeting GPCRs for endocrinology, immunology and inflammation, and metabolic diseases.

4 investors

SeqOne provides a clinical genomics analysis platform for germline and somatic variant interpretation across panels, exomes, and genomes, supporting short and long-read sequencing. It offers tools such as a DiagAI variant-prioritization score and an automated data pipeline (SeqOne Flow), serving diagnostic labs and clinical genomics teams with a CE-IVD certified in vitro diagnostic medical device.

4 investors

4 investors

Sesh+ manufactures nicotine pouches as a smoke-free alternative product for adult consumers seeking discrete, flavored nicotine delivery options.

4 investors

Shattuck Labs is a biotechnology company developing biologic medicines targeting TNF receptors, including the TL1A/DR3 axis, for patients with cancer and inflammatory or life-altering diseases. It is built around proprietary protein-engineering platforms and a pipeline of immunotherapy drug candidates.

4 investors

Sift Biosciences develops T-cell immunotherapies for cancer and autoimmune diseases, using an AI-driven discovery platform combined with metagenomics and high-throughput cellular screening to identify microbially derived molecules that activate memory T cells. Its SIFT platform supports pipelines in oncology and autoimmunity, with the latter partnered with a large pharmaceutical company.

4 investors

Signatur Biosciences develops molecular diagnostic solutions using qPCR technology for in vitro diagnostics, targeting clinical and laboratory markets. The company aims to deliver advanced diagnostics on widely available instrumentation to expand access to cutting-edge healthcare globally.

4 investors